| Patents for A61K 31 - Medicinal preparations containing organic active ingredients (785,912) |
|---|
| 05/30/2006 | US7053071 Induction of apoptosis in cancer cells |
| 05/30/2006 | US7053070 Antiproliferative agents; anticarcinogenic agents; viricides |
| 05/30/2006 | US7053069 Pharmaceutical compositions and methods of using C-21 modified epothilone derivatives |
| 05/30/2006 | US7053068 Chitosan-thio-amidine conjugates and their cosmetic as well as pharmaceutic use |
| 05/30/2006 | US7053067 Carbohydrate containing mannose ; prevent binding of chlamydia to mammal cells |
| 05/30/2006 | US7053066 Food composition and weight loss method for treating obesity |
| 05/30/2006 | US7053065 Vitamin B12 and pemetrexed disodium combination therapies |
| 05/30/2006 | US7053064 Administering cytosine, creatine, adenosine |
| 05/30/2006 | US7053063 applying voltage across tissue, detecting ratio of electric current to voltage (impedance) as indication of electroporation, then adjusting voltage; electroconductivity |
| 05/30/2006 | US7053062 Compositions and methods for inducing gene expression |
| 05/30/2006 | US7053061 Vegetable oil phase containing dispersed Amphotercin B; water phase containing dissolved glycerin, mannitol, or dextrose tonicity modifiers; emulsifier such as natural phosphatides |
| 05/30/2006 | US7053060 Glucopyranosyloxybenzylbenzene derivatives, medicinal compositions containing the same and intermediates in the production thereof |
| 05/30/2006 | US7053059 Dialysis solutions with reduced levels of glucose degradation products |
| 05/30/2006 | US7053058 For inhibiting growth of prostatic adenocarcinoma, stomach cancer, breast cancer, endometrial, ovarian or other cancers of epithelial secretion, or benign prostate hyperplasia |
| 05/30/2006 | US7053057 Caspase inhibitors and uses thereof |
| 05/30/2006 | US7053056 Antiinflammatory agents; autoimmune disease; antiischemic agents |
| 05/30/2006 | US7053052 for enhancing immunogenicity activity of tumor cells; tumor/drug targets |
| 05/30/2006 | US7053050 administering erythropoietin receptor antagonist or mimetics thereof |
| 05/30/2006 | US7053041 Methods and compositions useful for inhibition of αvβ5mediated angiogenesis |
| 05/30/2006 | US7052913 capsules comprising biocompatible silica sol-gel matrices that encapsulate chemical intermediates or prodrugs that convert when contacted with tissues and/or fluids; grafting encapsulated L-amino acid decarboxylase in the brain to convert L-dopa to dopamine for prophylaxis of Parkinson's disease |
| 05/30/2006 | US7052911 Adjust concentration of plant protein using peracetic acid, salicylic acid; gene encoding transcription factor |
| 05/30/2006 | US7052909 activation of natural killer T-lymphocytes(NKT) using phosphatidylinositol mannoside(PIM); prophylaxis of skin disorders, cancers or tuberculosis |
| 05/30/2006 | US7052903 Compositions and methods for activating genes of interest |
| 05/30/2006 | US7052862 Lipoprotein associated phospholipase A2, inhibitors thereof and use of the same in diagnosis and therapy |
| 05/30/2006 | US7052860 Identification of Actinobacillus actinomycetemcomitans antigens for use in the diagnosis, treatment, and monitoring of periodontal diseases |
| 05/30/2006 | US7052850 Isolated human EDG-4 receptor |
| 05/30/2006 | US7052722 optionally comprises L-carnitine; synergistic effect on the loss of body fat without any undesired side effects |
| 05/30/2006 | US7052717 Storage stable thyroxine active drug formulations and methods for their production |
| 05/30/2006 | US7052715 Alcohol-free transdermal analgesic composition and processes for manufacture and use thereof |
| 05/30/2006 | US7052714 Ophthalmic adhesive preparations for percutaneous adsorption |
| 05/30/2006 | US7052708 matrix of biopolymers (e.g., a bioerodible polymer and/or a non-absorbable polymer) and repellant chemicals (e.g.,animal repellants such as alkaloids isolated from the family Narcissus) permits sustained release of the chemicals. |
| 05/30/2006 | US7052707 Pharmaceutical composition containing aminoacetonitril compounds and the use thereof for the preparation of a pharmaceutical composition for the treatment of endoparasitic pests in animals |
| 05/30/2006 | US7052704 Comprises fatty acid-conjugated products with disulfide linkage to proteins/peptides for delivery to cells; increases absorption and prolongs blood and tissue retention |
| 05/30/2006 | US7052703 T-cell receptorγ alternate reading frame protein, (TARP) and uses thereof |
| 05/30/2006 | US7052684 Methods of healing wounds and fibrotic disorders using IL-10 |
| 05/30/2006 | US7052683 comprising tris(hydroxymethyl)aminomethane, urea, beta-cyclodextrin and reduced glutathione; for absorbing hydrogen sulfide and carbon dioxide from the air |
| 05/30/2006 | US7052680 aerosols containing antiparkinsons drugs benzotropine, pergolide, amantadine, deprenyl and ropinerole, that have been heated on a solid support such as foil and condensed by passing through a flow of air |
| 05/30/2006 | US7052679 thin film of drugs; heating; dispensing as aerosol condensation |
| 05/30/2006 | US7052678 Particles for inhalation having sustained release properties |
| 05/30/2006 | US7052676 Interference with binding chemokines |
| 05/30/2006 | CA2413235C Processing method of lactonization in the preparation of statins |
| 05/30/2006 | CA2391659C Crystal forms of azithromycin |
| 05/30/2006 | CA2375908C Highly selective norepinephrine reuptake inhibitors and methods of using the same |
| 05/30/2006 | CA2354605C Diazabicyclooctane derivatives and therapeutic uses thereof |
| 05/30/2006 | CA2345582C Process for the preparation of the mesylate salt trihydrate of 1-(4-hydroxyphenyl)-2-(4-hydroxy-4-phenylpiperidin-1-yl)-1-propanol |
| 05/30/2006 | CA2321380C 6-azauracil derivatives as thyroid receptor ligands |
| 05/30/2006 | CA2267103C Pyrazolopyridylpyridazinone derivatives and process for the preparation thereof |
| 05/30/2006 | CA2264718C Solid coprecipitates for enhanced bioavailability of lipophilic substances |
| 05/30/2006 | CA2263663C Substituted gamma aminobutyric acids as pharmaceutical agents |
| 05/30/2006 | CA2251132C Use of phosphinyloxyalkyl and phosphonamidoalkyl derivatives of cyclopentane(ene) as therapeutic agents |
| 05/30/2006 | CA2237594C Fused imidazole derivatives as multidrug resistance modulators |
| 05/30/2006 | CA2217226C Controlled release formulation for water soluble drugs in which a passageway is formed in situ |
| 05/30/2006 | CA2217051C Epoxysuccinic acid derivatives |
| 05/30/2006 | CA2200220C Drug for tumor growth suppression |
| 05/30/2006 | CA2195243C Triazole compounds and the use thereof |
| 05/30/2006 | CA2165971C Methylphosphonic acid ester, process for preparing the same and its use |
| 05/30/2006 | CA2157668C Tricyclic 2,3,4,5-tetrahydro-1h-3-benzazepines, their use and preparation |
| 05/30/2006 | CA2141692C Prodrugs of imidazole carboxylic acids as angiotensin ii receptor antagonists |
| 05/30/2006 | CA2117377C Substituted amino alkyl compounds |
| 05/30/2006 | CA2106613C Benzoylguanidines, process for their preparation, their use as a medicament and medicament containing them |
| 05/30/2006 | CA2085831C Polymers and oligomers of bile acid derivatives, process for their preparation and their use as pharmaceuticals |
| 05/26/2006 | WO2006055964A2 Zolmitriptan crystal forms |
| 05/26/2006 | WO2006055954A2 Steroid formulation and methods of treatment using same |
| 05/26/2006 | WO2006055951A2 Tetrahydroisoquinolines as factor xa inhibitors |
| 05/26/2006 | WO2006055879A2 Novel phosphorous containing steroid mimics |
| 05/26/2006 | WO2006055875A2 Methods and compositions related to esculentoside a |
| 05/26/2006 | WO2006055854A2 Methods for reducing the side effects associated with mirtazapine treatment |
| 05/26/2006 | WO2006055841A2 Indefinite culture of human adult glia without immortalization and therapeutic uses thereof |
| 05/26/2006 | WO2006055833A2 Gtpase inhibitors and use thereof for controlling platelet hyperactivity |
| 05/26/2006 | WO2006055831A2 Kinase inhibitors |
| 05/26/2006 | WO2006055764A2 Use of methyl pyruvate to increase cellular energy production downstream of glycolysis |
| 05/26/2006 | WO2006055760A1 Triazole compounds that modulate hsp90 activity |
| 05/26/2006 | WO2006055754A1 Method for treating hiv infection through co-administration of tipranavir and reverset |
| 05/26/2006 | WO2006055752A2 INHIBITORS OF 11-β HYDROXYL STEROID DEHYDROGENASE TYPE 1 AND METHODS OF USING THE SAME |
| 05/26/2006 | WO2006055747A2 Bis(thio-hydrazide amides) for increasing hsp70 expression |
| 05/26/2006 | WO2006055726A2 Composition and method for facilitating the healing of non-healing and slow-healing wounds and ulcerations |
| 05/26/2006 | WO2006055725A2 Substituted amino acids as protein tyrosine phosphatase inhibitors |
| 05/26/2006 | WO2006055711A1 Compositions containing aloe vera isolate and a prebiotic and their therapeutic application |
| 05/26/2006 | WO2006055694A1 Novel 2h-chromene derivatives as selective estrogen receptor modulators |
| 05/26/2006 | WO2006055672A2 Methods and compositions for treating pain |
| 05/26/2006 | WO2006055663A2 The use of novel antibacterial compounds |
| 05/26/2006 | WO2006055660A2 Method for treating hiv infection through co-administration of tipranavir and uk-427, 857 |
| 05/26/2006 | WO2006055659A2 Fixed dose combination op dutasteride and tamsulosin |
| 05/26/2006 | WO2006055632A2 Pharmaceutical manufacturing process for heat sterilized glucocorticoid suspensions |
| 05/26/2006 | WO2006055625A2 Heterocyclylbiphenyl derivates as protein tyrosine phosphatase inhibitors |
| 05/26/2006 | WO2006055597A1 Use of ribose-cysteine to treat hypoxia by enhancing delivery of glutathione and atp levels in cells |
| 05/26/2006 | WO2006055578A2 Asymmetric synthesis of (-)-agelastatin a |
| 05/26/2006 | WO2006055573A2 Methods of using pde v inhibitors for the treatment of congestive heart failure |
| 05/26/2006 | WO2006055565A2 Control of parasites in animals by the use of parasiticidal 2-phenyl-3-(1h-pyrrol-2-yl) acrylonitrile derivatives |
| 05/26/2006 | WO2006055561A2 Stereoisomerically enriched 3-aminocarbonyl bicycloheptene pyrimidinediamine compounds and their uses |
| 05/26/2006 | WO2006055553A2 Novel m3 muscarinic acetylcholine receptor antagonists |
| 05/26/2006 | WO2006055542A2 Diuretic compounds comprising heterocyclic nitric oxide donor groups, compositions and methods of use |
| 05/26/2006 | WO2006055526A2 Compositions useful to treat ocular neovascular diseases and macular degeneration |
| 05/26/2006 | WO2006055525A2 Protein tyrosine phosphatase inhibitors and methods of use thereof |
| 05/26/2006 | WO2006055511A2 Stable tablet formulation of tetrahydrobiopterin |
| 05/26/2006 | WO2006055503A2 Novel m3 muscarinic acetylcholine receptor antagonists |
| 05/26/2006 | WO2006055481A1 2,3,4-substituted cyclopentanones as therapeutic agents |
| 05/26/2006 | WO2006055472A2 Synthetic discodermolide analogs |
| 05/26/2006 | WO2006055463A2 2-amino-3-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |
| 05/26/2006 | WO2006055462A1 2-amino-4-functionalized tetralin derivatives and related glycogen phosphorylase inhibitors |